Clinical trial
Efficacy and Safety Study of rhuMAb VEGF to Treat Metastatic Renal Cell…
NCT00061178 · Genentech, Inc., Industry · Withdrawn
Key facts
| NCT number | NCT00061178 |
|---|---|
| Title | Efficacy and Safety Study of rhuMAb VEGF to Treat Metastatic Renal Cell Carcinoma |
| Official title | Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Efficacy & Safety of rhuMAb VEGF in Previously Treated Metastatic Renal Cell Carcinoma |
| Lead sponsor | Genentech, Inc., Industry |
| Status | Withdrawn |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Renal Cell Cancer |
| Intervention type | Drug |
| Interventions | rhuMAb VEGF (Bevacizumab) |
| Enrollment | 0 |
| First posted | May 23, 2003 |
| Last update posted | Oct 19, 2016 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: